An FDA advisory committee voted 13-1 in support of the efficacy of a hepatitis B vaccine on Thursday but questioned its safety and lack of information on its effects among certain minorities.
- Published
- 19 November 2012
- From
-
MedPage Today
A new US study provides more evidence of
the disproportionate impact of viral hepatitis infections on the 'baby boom'
generation. Writing in the online edition of Clinical
- Published
- 11 November 2012
- By
- Michael Carter
Incidence of liver cancer among people with HIV has increased dramatically over the past decade, Spanish investigators
report in the online edition of Clinical
Infectious Diseases. All
- Published
- 29 October 2012
- By
- Michael Carter
A research team has discovered two prime targets of the Hepatitis B virus in liver cells, findings that could lead to treatment of liver disease in some of the 400 million people worldwide currently infected with the virus.
- Published
- 23 October 2012
- From
-
Science Daily
Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.
- Published
- 27 September 2012
- From
-
HIVandHepatitis.com
People with HIV and hepatitis B virus (HBV)
co-infection, who substituted tenofovir (Viread) for zidovudine (Retrovir)
or abacavir (Ziagen) in their
antiretroviral regimen, saw a reduction in hepatitis
- Published
- 20 September 2012
- By
- Liz Highleyman
Nearly all children who received three doses of
hepatitis B vaccine achieved immunity, but about 20% fell below the protective
antibody threshold by year 15, Canadian researchers
- Published
- 12 September 2012
- By
- Liz Highleyman
The Viread label was updated to include dosing information for the treatment of chronic hepatitis B infection in patients 12 years of age and older, and to add 240 week data in adults to the package insert.
- Published
- 30 August 2012
- From
-
EATG
Viral hepatitis B and C, which can cause life-threatening damage to the liver, can be the unintended consequence of two recent social trends: diabetes curiosity and self-inking/piercing.
'Diabetes curiosity' refers to those who use someone else’s lancet and glucose meter diabetes testing devices to prick themselves to test their own blood sugar levels.
Self-inkers/piercers are people who use needles or other devices to create tattoos or pierce themselves or friends. In both cases, a life-threatening hepatitis infection can spread quickly from one person to another.
“We have concerns about people borrowing someone else’s diabetes testing equipment to see what their own blood sugar levels are,” said State Epidemiologist Tim Jones, MD. “With these devices now commonplace, the testing process can generate curiosity. Parents need to know and remind children who use the devices not to share them with others, and parents of non-diabetic children should teach everyone in their family to never, ever experiment with another person’s insulin-related equipment.”
- Published
- 22 August 2012
- From
-
HCV New Drugs Research
An estimated 25 million Indonesians have either had hepatitis B or C, but only about 20 percent of them know, said Rino Gani, the chairman of the Indonesian Liver Research Association.
- Published
- 17 August 2012
- From
-
IRINnews.org
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...